Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells $1,321,076.82 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Adrian Krainer sold 33,243 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total value of $1,321,076.82. Following the completion of the transaction, the director directly owned 283,302 shares in the company, valued at $11,258,421.48. This trade represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Stoke Therapeutics Trading Down 9.0%

STOK stock opened at $33.19 on Friday. The company has a market cap of $1.90 billion, a PE ratio of 49.54 and a beta of 1.07. The stock has a 50-day moving average price of $32.71 and a two-hundred day moving average price of $29.63. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $40.22.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Stoke Therapeutics by 5.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after acquiring an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after acquiring an additional 293,072 shares in the last quarter. Jane Street Group LLC grew its position in Stoke Therapeutics by 125.2% in the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after acquiring an additional 15,001 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Stoke Therapeutics during the second quarter valued at approximately $224,000. Finally, Aviva PLC purchased a new stake in shares of Stoke Therapeutics during the second quarter valued at approximately $499,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on STOK. UBS Group set a $50.00 target price on Stoke Therapeutics in a report on Monday, December 15th. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a research report on Monday, January 5th. Guggenheim started coverage on shares of Stoke Therapeutics in a research note on Thursday, February 5th. They set a “buy” rating and a $60.00 price objective for the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Finally, Wedbush raised their target price on shares of Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $39.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.